pemoline has been researched along with amantadine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bavazzano, A; D'Ayalavalva, G; Montanari, C; Sanesi, P; Vallecorsi, GF | 1 |
| Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L | 1 |
| Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M | 1 |
| Dulli, D; Schutta, H | 1 |
| Hohlfeld, R; Zimmermann, C | 1 |
| Brañas, P; Burls, A; Fry-Smith, A; Hyde, C; Jordan, R | 1 |
| Christodoulou, C; Krupp, LB | 1 |
| Murray, TJ; Schwid, SR | 1 |
| Boërio, D; Créange, A; Hogrel, JY; Lefaucheur, JP | 1 |
| Hum, S; Lapierre, Y | 1 |
| Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P | 1 |
| Kirshbaum, M | 1 |
| Constantinescu, CS; Gran, B; Induruwa, I | 1 |
| Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P | 1 |
| Deng, XY; Wang, L; Yang, TT; Yu, G | 1 |
11 review(s) available for pemoline and amantadine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
['Fatigue' in multiple sclerosis].
Topics: Amantadine; Aminopyridines; Disease Progression; Fatigue; Female; Humans; Male; Multiple Sclerosis; Pemoline; Potassium Channel Blockers; Severity of Illness Index | 1999 |
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
Topics: Amantadine; Central Nervous System Stimulants; Cost-Benefit Analysis; Dopamine Agents; Evidence-Based Medicine; Fatigue; Humans; Multiple Sclerosis; Pemoline | 2000 |
Fatigue in multiple sclerosis.
Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous System Stimulants; Combined Modality Therapy; Cross-Over Studies; Depression; Double-Blind Method; Fatigue; Hot Temperature; Humans; Hypothalamus; Methylphenidate; Modafinil; Multiple Sclerosis; Patient Care Team; Pemoline; Physical Therapy Modalities; Pilot Projects; Randomized Controlled Trials as Topic; Self-Assessment; Severity of Illness Index; Tomography, Emission-Computed | 2001 |
[Pathophysiology and treatment of fatigue in multiple sclerosis].
Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central Nervous System; Chronic Disease; Fatigue; Humans; Mental Fatigue; Modafinil; Multiple Sclerosis; Pemoline; Peripheral Nervous System; Physical Exertion; Severity of Illness Index; Surveys and Questionnaires | 2006 |
Treating fatigue.
Topics: Amantadine; Central Nervous System Stimulants; Comorbidity; Diagnosis, Differential; Dopamine Agents; Evidence-Based Medicine; Fatigue; Humans; Multiple Sclerosis; Patient Care Team; Pemoline | 2007 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney Failure, Chronic; Methylphenidate; Modafinil; Multiple Sclerosis; Neoplasms; Palliative Care; Pemoline; Randomized Controlled Trials as Topic | 2010 |
Pharmacologic treatments for fatigue associated with palliative care.
Topics: Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Evidence-Based Medicine; Fatigue; Humans; Modafinil; Palliative Care; Pemoline; Randomized Controlled Trials as Topic | 2011 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Cytokines; Depression; Diffuse Axonal Injury; Double-Blind Method; Exercise Therapy; Fatigue; Humans; Hypothalamo-Hypophyseal System; Immunologic Factors; Modafinil; Multiple Sclerosis; Pemoline; Pituitary-Adrenal System; Quality of Life; Single-Blind Method; Sleep Disorders, Intrinsic | 2012 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disease; Fatigue; Humans; Kidney Failure, Chronic; Methylphenidate; Modafinil; Multiple Sclerosis; Neoplasms; Palliative Care; Pemoline; Randomized Controlled Trials as Topic | 2015 |
Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
Topics: 4-Aminopyridine; Amantadine; Central Nervous System Stimulants; Dopamine Agents; Drug Therapy; Fatigue; Humans; Multiple Sclerosis; Pemoline | 2017 |
3 trial(s) available for pemoline and amantadine
| Article | Year |
|---|---|
Clinical trial with amantadine and pemoline in elderly patients.
Topics: Aged; Amantadine; Clinical Trials as Topic; Humans; Pemoline; Placebos; Psychomotor Disorders | 1976 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind Method; Fatigue; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Pemoline | 1995 |
The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Attention; Central Nervous System Stimulants; Cognition; Fatigue; Female; Humans; Male; Memory; Middle Aged; Movement; Multiple Sclerosis; Neuropsychological Tests; Pemoline | 1996 |
5 other study(ies) available for pemoline and amantadine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Fatigue in MS.
Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis; Pemoline | 1996 |
Treating fatigue in patients with MS: one step forward, one step back.
Topics: Amantadine; Aspirin; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants; Cross-Over Studies; Dopamine Agents; Fatigue; Humans; Modafinil; Multiple Sclerosis; Pemoline; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |